drugset / Trial / NCT00528255

Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)

NCT00528255

Phase 2 Withdrawn Ferring Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will provide pharmacokinetic data for the MVI 100 (100 mcg) misoprostol vaginal insert when administered to nulliparous women at term gestation requiring cervical ripening and induction of labor.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 100 ug Other

Indications